Form 4: ADMA Biologics CEO Adam Grossman Reports Changes in Beneficial Ownership

Adam Grossman, President, CEO, and Interim CFO of ADMA Biologics, reports changes in beneficial ownership of company stock due to tax withholding upon vesting of restricted stock units.

Summary

• On March 31, 2024, Adam Grossman, President, CEO, and Interim CFO of ADMA Biologics, filed a Form 4 with the SEC reporting changes in his beneficial ownership of ADMA stock.
• The filing indicates that 21,752 shares were withheld by the issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units (RSUs) at a price of $6.6 per share.
• Following the transaction, Grossman directly owns 2,651,475 shares of common stock.
• Grossman also indirectly owns 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC.
• The filing also includes details about unvested RSUs that will vest quarterly over the next few years.
• A Limited Power of Attorney was executed on March 28, 2024, appointing Michael A. Goldstein to handle Section 16(a) reporting on Grossman's behalf.

Sentiment

Score: 5

Explanation: This is a neutral filing regarding stock ownership changes due to standard tax withholding procedures. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This is a routine filing related to executive compensation and stock ownership, common in publicly traded companies.

Stakeholder Impact

• The transaction has a minor impact on the overall share count.
• Shareholders may be interested in executive compensation and ownership structure.

Key Dates